Elevated maternal serum alpha-fetoprotein caused by midtrimester amniocentesis: a prognostic factor

Area of Science:

• Maternal-Fetal Medicine
• Diagnostic Procedures
• Prenatal Screening

Background:

• Midtrimester amniocentesis is a common prenatal diagnostic procedure.
• Maternal serum alpha-fetoprotein (AFP) is a key biomarker in prenatal screening.
• Elevated AFP levels can indicate fetal abnormalities or complications.

Purpose of the Study:

• To investigate the incidence and implications of fetal-maternal bleeding following ultrasonically guided amniocentesis.
• To assess the correlation between amniocentesis-induced bleeding and placental location.
• To evaluate the impact of such bleeding on fetal birth weight and gestational age.

Main Methods:

• Prospective study of 247 patients undergoing midtrimester amniocentesis.
• Measurement of maternal serum alpha-fetoprotein (AFP) before and after the procedure.
• Correlation analysis of AFP elevation, placental location, and fetal birth weight.

Main Results:

• Amniocentesis induced significant AFP elevation (indicating fetal-maternal bleeding) in 21.0% of patients with pre-procedure AFP > 19 µg/L.
• This bleeding was significantly correlated with anterior placental location (P < .025).
• Patients experiencing bleeding had a significantly reduced mean fetal birth weight (3143 vs. 3385 g, P < .05).

Conclusions:

• Ultrasonically guided amniocentesis can pose a risk of fetal-maternal bleeding.
• Anterior placental location increases the likelihood of this complication.
• Amniocentesis-induced bleeding may negatively impact fetal growth, warranting consideration given its expanding indications.